In ACS acute tx, which antiplatelet combination is typical?

• A. Clopidogrel alone
• B. Aspirin + a P2Y12 inhibitor
• C. No antiplatelet therapy
• D. Aspirin alone

Answer: (B)

In acute coronary syndrome, the aim is rapid and strong inhibition of platelet activation to prevent clot growth and recurrent ischemia. The typical approach is dual antiplatelet therapy: aspirin, which irreversibly blocks platelet COX-1 and reduces thromboxane A2 formation, plus a P2Y12 receptor inhibitor that prevents ADP-mediated platelet activation and aggregation. Using both targets the two main pathways of platelet activation, giving a more robust antithrombotic effect than either agent alone. Clopidogrel alone wouldn’t address the rapid ADP-driven activation that aspirin doesn’t fully inhibit, and aspirin alone leaves a significant residual risk. Omitting antiplatelet therapy in ACS markedly increases the risk of recurrent events. Therefore, the standard combo is aspirin plus a P2Y12 inhibitor (options include clopidogrel, prasugrel, or ticagrelor, chosen based on clinical context).